Celltrion Files Subcutaneous Infliximab In US – As Standalone BLA

‘Biobetter’ Submitted To FDA As Biologic Via 351(a) Pathway, Not As A Biosimilar

Celltrion is seeking US approval for its subcutaneous formulation of infliximab, marketed in other territories as Remsima SC. The product will be registered as a standalone biologic rather than a biosimilar.

FDA building.
Celltrion has filed its subcutaneous infliximab with the FDA • Source: Shutterstock

Celltrion has pushed forward with plans to bring its novel subcutaneous version of infliximab to the US market, even if it means having to file the product via a standalone biologics license application rather than as a biosimilar.

The Korean firm’s CT-P13 subcutaneous infliximab product – marketed in other territories as Remsima SC, an innovative variant of its...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.